BI-4659

Overview

BI-4659 is a TGFβRI and PDGFRα inhibitor with IC 50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα , blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1 . BI-4659 is applicable to research related to pulmonary fibrosis, cancer , and renal ischemia-reperfusion injury.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-171878
• CAS No.: 894784-05-5
• Molecular Formula: C27H28N4O2
• Molecular Weight: 440.54
• Purity: 99.78%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source